Advertisement
Screener

SCIENTURE HOLDINGS, INC. (SCNX) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures

2.8 / 5 stars · 68/120 Roast Me

SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures

SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 202 shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-22.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2024-04-22

  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2022-12-31 was -2.83K shares.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2022-09-30 was 0.00 shares.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2022 was 202.00 shares, a 99.47% decline from fiscal 2021.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2021 was 38.22K shares, a 14.64% increase from fiscal 2020.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2020 was 33.34K shares, a 1100.00% increase from fiscal 2019.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2019 was 2.78K shares, a 96.17% decline from fiscal 2018.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month as first filed
2022-12-31-2.83K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22
-2.83K shares
derived: sum of 2 quarters · filed 2024-04-22
202.00 shares
10-K · filed 2024-04-22
3.03K shares
10-K · filed 2023-03-27
2022-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
3.03K shares
10-Q · filed 2022-11-07
2022-06-303.03K shares
10-Q · filed 2022-07-25
2021-12-3138.22K shares
10-K · filed 2023-03-27
2020-12-3133.34K shares
10-K · filed 2022-03-28
2019-12-312.78K shares
10-K · filed 2020-03-30
2018-12-3172.50K shares
10-K · filed 2020-03-30
435.00K shares
10-K · filed 2019-03-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33